Summary of Purpose
Objectives - Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. - Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.Read More →
The following dates are available for this trial. Trial information last updated on 17 February 2018.
|19 Jan 2018||16 Jun 2017||18 Jan 2022||30 Apr 2022||1 Feb 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Sponsors See All